Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a significant decline in short interest in February. As of February 15th, there was short interest totalling 14,400 shares, a decline of 12.2% from the January 31st total of 16,400 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 45,100 shares, the days-to-cover ratio is presently 0.3 days.

Cocrystal Pharma Trading Up 2.8 %

Shares of COCP stock traded up $0.05 during mid-day trading on Thursday, reaching $1.77. The stock had a trading volume of 5,466 shares, compared to its average volume of 31,197. The company has a market cap of $18.00 million, a P/E ratio of -0.96 and a beta of 2.35. Cocrystal Pharma has a 12-month low of $1.35 and a 12-month high of $3.26. The business has a 50-day simple moving average of $2.05 and a 200 day simple moving average of $1.96.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Cocrystal Pharma in a report on Wednesday, January 22nd.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.